Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease

Atherosclerosis

Volumn 222, Issue 2, 2012, Pages 530-536

  Theken, Katherine N ^a   Schuck, Robert N ^a   Edin, Matthew L ^d   Tran, Bryant ^a   Ellis, Kyle ^a   Bass, Almasa ^a   Lih, Fred B ^d   Tomer, Kenneth B ^d   Poloyac, Samuel M ^e   Wu, Michael C ^b   Hinderliter, Alan L ^c   Zeldin, Darryl C ^d   Stouffer, George A ^c   Lee, Craig R ^a,c  

^a University of North Carolina   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

20 Hydroxyeicosatetraenoic acid; Arachidonic acid; Coronary artery disease; Dihydroxyeicosatrienoic acid; Epoxyeicosatrienoic acid; Soluble epoxide hydrolase

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ALKANE 1 MONOOXYGENASE; CYTOCHROME P450; DIHYDROXYICOSATRIENOIC ACID; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ICOSANOID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME METABOLISM; FATTY ACID BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; OBESITY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

8,11,14-EICOSATRIENOIC ACID; AGE FACTORS; ALKANE 1-MONOOXYGENASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS; EICOSANOIDS; EPOXIDE HYDROLASES; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; HYDROXYLATION; MALE; MIDDLE AGED; NORTH CAROLINA; OBESITY; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; TANDEM MASS SPECTROMETRY;

EID: 84861346664     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.03.022     Document Type: Article

References (30)

1. Deng Y., Theken K.N., Lee C.R. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 2010, 48:331-341.
2. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002, 82:131-185.
3. Lee C.R., Imig J.D., Edin M.L., et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010, 24:3770-3781.
4. Deng Y., Edin M.L., Theken K.N., et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 2011, 25:703-713.
5. Wu C.C., Cheng J., Zhang F.F., et al. Androgen-dependent hypertension is mediated by 20-hydroxy-5,8,11,14-eicosatetraenoic acid-induced vascular dysfunction: role of inhibitor of kappaB Kinase. Hypertension 2011, 57:788-794.
6. Zhang L.N., Vincelette J., Cheng Y., et al. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol 2009, 29:1265-1270.
7. Seubert J.M., Sinal C.J., Graves J., et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 2006, 99:442-450.
8. Nithipatikom K., Gross E.R., Endsley M.P., et al. Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res 2004, 95:e65-e71.
9. Fava C., Montagnana M., Almgren P., et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension 2008, 52:373-380.
10. Gainer J.V., Bellamine A., Dawson E.P., et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005, 111:63-69.
11. Lee C.R., North K.E., Bray M.S., et al. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics 2007, 17:349-358.
12. Lee C.R., North K.E., Bray M.S., et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006, 15:1640-1649.
13. Theken K.N., Lee C.R. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. Pharmacogenomics 2007, 8:1369-1383.
14. Chen D., Whitcomb R., Macintyre E., et al. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects. J Clin Pharmacol 2012, 52:319-328.
15. Williams J.M., Murphy S., Burke M., et al. 20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. J Cardiovasc Pharmacol 2010, 56:336-344.
16. Edin M.L., Wang Z., Bradbury J.A., et al. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J 2011, 25:3436-3447.
17. Zhao X., Dey A., Romanko O.P., et al. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2005, 288:R188-R196.
18. Theken K.N., Deng Y., Schuck R.N., et al. Enalapril reverses high fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab 2012, 302:E500-E509.
19. Omata K., Abraham N.G., Escalante B., et al. Age-related changes in renal cytochrome P-450 arachidonic acid metabolism in spontaneously hypertensive rats. Am J Physiol 1992, 262:F8-F16.
20. Shimojo N., Ishizaki T., Imaoka S., et al. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 1993, 46:621-627.
21. Maresh J.G., Xu H., Jiang N., et al. Tobacco smoke dysregulates endothelial vasoregulatory transcripts in vivo. Physiol Genomics 2005, 21:308-313.
22. *7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2007, 195:199-206.
23. Minuz P., Jiang H., Fava C., et al. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension 2008, 51:1379-1385.
24. Croft K.D., McGiff J.C., Sanchez-Mendoza A., et al. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol 2000, 279:F544-F551.
25. Laffer C.L., Laniado-Schwartzman M., Nasjletti A., et al. 20-HETE and circulating insulin in essential hypertension with obesity. Hypertension 2004, 43:388-392.
26. Ward N.C., Rivera J., Hodgson J., et al. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 2004, 110:438-443.
27. Lee C.R., Pretorius M., Schuck R.N., et al. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans. Hypertension 2011, 57:116-122.
28. Monti J., Fischer J., Paskas S., et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 2008, 40:529-537.
29. Di Angelantonio E., Chowdhury R., Sarwar N., et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009, 120:2177-2187.
30. Oguro A., Fujita N., Imaoka S. Regulation of soluble epoxide hydrolase (sEH) in mice with diabetes: high glucose suppresses sEH expression. Drug Metab Pharmacokinet 2009, 24:438-445.